Repository logo
 
Publication

Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group

dc.contributor.authorJanez, A
dc.contributor.authorMuzurovic, E
dc.contributor.authorStoian, A
dc.contributor.authorHaluzik, M
dc.contributor.authorGuja, C
dc.contributor.authorCzupryniak, L
dc.contributor.authorDuvnjak, L
dc.contributor.authorLalic, N
dc.contributor.authorTankova, T
dc.contributor.authorBogdanski, P
dc.contributor.authorPapanas, N
dc.contributor.authorSilva Nunes, J
dc.contributor.authorKempler, P
dc.contributor.authorFras, Z
dc.contributor.authorRizzo, M
dc.date.accessioned2024-03-08T16:28:46Z
dc.date.available2024-03-08T16:28:46Z
dc.date.issued2022
dc.description.abstractGlucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationInt J Cardiol . 2022 Oct 15:365:8-18.pt_PT
dc.identifier.doi10.1016/j.ijcard.2022.07.017pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4835
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.subjectHCC ENDpt_PT
dc.subjectHumanspt_PT
dc.subjectCardiovascular Diseases* / drug therapypt_PT
dc.subjectCardiovascular Diseases* / epidemiologypt_PT
dc.subjectDiabetes Mellitus, Type 2* / diagnosispt_PT
dc.subjectDiabetes Mellitus, Type 2* / drug therapypt_PT
dc.subjectDiabetes Mellitus, Type 2* / epidemiologypt_PT
dc.subjectGlucagon-Like Peptide 1 / metabolismpt_PT
dc.subjectGlucagon-Like Peptide-1 Receptor / agonistspt_PT
dc.subjectHypoglycemic Agents / pharmacologypt_PT
dc.subjectHypoglycemic Agents / therapeutic usept_PT
dc.subjectLiraglutide / pharmacologypt_PT
dc.subjectLiraglutide / therapeutic usept_PT
dc.titleTranslating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Grouppt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage18pt_PT
oaire.citation.startPage8pt_PT
oaire.citation.titleInternational Journal of Cardiologypt_PT
oaire.citation.volume365pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
IJC 2022 8.pdf
Size:
2.03 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections